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Abstract
In May 2005, the Food and Drug Administration (FDA) issued draft guidance
on the type of information to be posted on its new “Drug Watch” website—a site
intended to identify drugs for which it is actively evaluating early safety signals.
At this time, the FDA plans only to post information on drug products regulated by
the Center for Drug Evaluation and Research, therefore vaccines, blood products
and medical devices shall be excluded.
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UNITED STATES
FDA Issues Guidance Describing New 
Drug Safety Website for Emerging Risks
In May 2005, the Food and Drug Administration 
(FDA) issued draft guidance on the type of 
information to be posted on its new “Drug 
Watch” website—a site intended to identify drugs 
for which it is actively evaluating early safety 
signals. At this time, the FDA plans only to post 
information on drug products regulated by the 
Center for Drug Evaluation and Research, 
therefore vaccines, blood products and medical 
devices shall be excluded. 
In its guidance, the FDA identified several 
factors that it plans to consider when 
determining what products and information 
to post on this site, including whether:
• New and emerging safety information 
could significantly affect prescribing 
decisions or how patients should be 
monitored (e.g., a new possible drug-drug 
interaction has been identified and needs 
to be considered in prescribing)
• Measures may be taken by providing 
information that could help to prevent or 
mitigate harm (e.g., limit prescribing to patients 
most likely to benefit from the drug, be alert 
for signs of serious adverse reactions)
• An unapproved (off-label) use of the drug 
appears to pose a significant risk to patients 
The FDA indicated that it intends to remove 
products from the website as safety issues 
are resolved. The guidance also warned 
manufacturers about the consequences of 
emphasizing a competitor’s listing on the Drug 
Watch site or minimizing the effect of its own 
listing, indicating that neither the fact that a 
drug appears on Drug Watch nor the specific 
information posted about it will generally 
constitute substantial evidence or clinical 
experience to support a comparative safety or 
effectiveness claim. Accordingly, comparative 
claims made in prescription drug promotion 
based on information posted on the site may be 
considered false or misleading marketing, as may 
a company’s representations made to minimize 
the effect of its own emerging risk information.
FDA Guidance
EUROPE
Abridged Marketing Authorization 
Applies to Line Extension Product 
with Different Dosage Schedule
In the most recent of four actions testing 
the boundaries of the abridged marketing 
authorization provisions relating to medicinal 
products for human use, the UK High Court has 
held—despite the fact that the European Court 
of Justice (ECJ) has not specifically previously 
considered the issue—where the data relied 
upon relates to an authorized product (itself a 
line extension of an earlier authorized product 
with a different dosage schedule) the principles 
set out in the three previous cases apply. As a 
result, the three generic applicants in the case 
were entitled to rely on such data, without 
addition, and a further reference on interpreta-
tion to the ECJ was held to be unnecessary.
Merck Sharp and Dohme had challenged the 
entitlement of the applicants to rely upon 
data relating to two authorized osteoporosis 
products in order to seek abridged marketing 
authorization for their own products. EC 
legislation states that abridged marketing 
authorization may be sought where the applicant 
can show that its product is “essentially similar” 
to one that has been authorized for 10 years 
(UK). The ECJ has held that data relating to 
products authorized for less than this period, 
but differing only in therapeutic indication, 
bioavailability or pharmaceutical form to one 
Baltimore
Beijing
Berlin
Boston
 
Brussels
 
London
Munich
 
New York
Northern Virginia
 
Oxford
Palo Alto
 
Waltham
 
Washington
wilmerhale.com Hosted by The Berkeley Electronic Press
so authorized, may be relied upon, provided the 
test of “essential similarity” (same qualitative and 
quantitative composition, same pharmaceutical 
form, bioequivalent and no significant difference 
in safety or efficacy) remains satisfied.
Merck v. Approved Prescription Services
Automatic Validity of Swiss Marketing 
Authorizations in Liechtenstein 
Impacts Duration of Supplementary 
Protection Certificates
The ECJ has recently clarified that the automatic 
validity of Swiss marketing authorizations in 
the European Economic Area (EEA) member 
state of Liechtenstein—result of a mutual 
recognition agreement between these two 
countries—means that such authorizations do 
constitute the “first marketing authorization 
in the community” for the purpose of granting 
Supplementary Protection Certificates (SPC). 
On joined references from the UK Patent Office 
and the Luxembourg Administrative Court, Swiss 
marketing authorizations were obtained several 
months before authorizations in an EEA member 
state other than Liechtenstein. The patentees 
argued that the SPC sought should run from 
the date of the later authorizations. The ECJ 
disagreed on the basis that this would mean that 
the patent and SPC holders should be able to take 
advantage of more than the permitted 15 years’ 
exclusivity from the date of first authorization. 
SPC may be granted for any active ingredient(s), 
protected by patent and present in medicinal 
products that have received EEA marketing 
authorization. SPC confer the same rights as 
the patent and take effect at the end of its term 
for a period equal to that elapsing between 
the date the patent application was lodged and 
the date of the first EEA authorization. SPC 
compensate for the delay in commercialization 
caused by the authorization procedure. The 
maximum duration of an SPC is five years. 
This decision may have significant impact for 
relevant patent holders. Many such patentees seek 
early authorization in Switzerland prior to placing 
their respective products on the EEA market some 
months later. By calculating extended protection 
from the date of this earlier authorization, these 
patentees may now face significant profit losses. 
In the case referred by the Luxembourg Court, 
the patentee lost protection for a period greater 
than two years. Patentees will now have to take 
care that their Swiss marketing approvals do 
not proceed faster than their EEA approvals.
Novartis v. Licensing Authorities
INTELLECTUAL PROPERTY
UNITED STATES 
En Banc Review Denied
The Spring 2005 issue of PharmaBulletin reported 
that the Federal Trade Commission (FTC) had filed 
a brief in support of the generic drug manufacturer 
to have the US Court of Appeals for the Federal 
Circuit review a panel decision en banc as to 
whether Teva—an ANDA applicant who had filed 
a paragraph IV certification—had a reasonable 
apprehension of suit to create jurisdiction for its 
declaratory judgment action. On April 4, 2004, this 
petition was denied (Teva Pharmaceuticals v. Pfizer). 
This closely watched and controversial 
decision is important for both pharmaceutical 
and generic companies to consider in their 
strategic decisions on patent enforcement 
and generic competitor product launch.
Teva had filed an ANDA application, with a 
paragraph IV certification, seeking approval from 
the FDA to market its generic version of Pfizer’s 
Zoloft® (sertraline hydrochloride), before Pfizer’s 
patent expired. Under the provisions of the 
Hatch-Waxman Act, Pfizer had 45 days to sue 
Teva for patent infringement. When Pfizer did not 
sue, Teva brought a declaratory judgment action 
against Pfizer, seeking a determination that its 
generic product did not infringe Pfizer’s patent.
The court held that merely listing a patent 
in the Orange Book does not illustrate a 
“reasonable apprehension” of being sued, 
because listing is a statutory requirement, 
“more is required for an actual controversy than 
the existence of an adversely held patent.”
Judges Garja and Dyk wrote dissenting opinions 
on the denial. Judge Garja asserted that the panel 
decision allowed “the statutory procedures to 
be manipulated by the patent holders to the 
clear and foreseeable detriment of the generic 
drug industry.” Judge Dyk wanted the en banc 
rehearing granted in order to answer the question 
as to “whether a patent holder can delay [FDA] 
approval of an application for a competing generic 
drug by the simple expedient of refusing to 
sue for infringement.” These opinions portend 
further amendments to the Hatch-Waxman 
Act. In the meantime, patentees may consider 
not suing generic companies who have filed an 
ANDA with a paragraph IV certification, as an 
alternative strategy to Hatch-Waxman litigation.
Teva Pharmaceuticals USA Inc. v. Pf izer Inc.
2003 Medicare Act
“UK Court of Appeal  
further develops  
principles of patent 
claim construction.”
http://law.bepress.com/wilmer/art11
EUROPE 
UK Court of Appeal Further Develops 
Principles of Patent Claim Construction
Hot on the heels of the House of Lords 
decision in Kirin-Amgen, the Court of Appeal has 
taken the opportunity to further develop the 
principles of the construction of patent claims.
The claimants, Mayne Pharma Pty Ltd and 
Mayne Pharma Plc, initiated proceedings seeking 
a declaration of non-infringement relating 
to four patents owned by the defendant, 
Pharmacia Italia SpA. Pharmacia Italia coun-
terclaimed for infringement of one of these 
patents, relating to an injectable ready-to-use 
anticancer solution not “reconstituted from 
a lyophilizate.” The sole issue at trial was the 
interpretation of claim one of that patent. 
Finding for Pharmacia Italia, the Court of Appeal 
held, contrary to the trial court, that the patent 
was infringed by Mayne Pharma’s product, 
which had been subjected to a lyophilization 
process. Its reason was that a pharmaceutical 
manufacturer (the correct notional person 
skilled in the art) would see that the essence 
of the invention was the manufacture of a 
ready-to-use solution that  did not involve the 
previously essential lyophilization stage.
In a short 10-page judgment, the court 
noted with approval that the case had been 
subjected to the streamlined procedure, going 
“from start to determination on appeal in 
less than 9 months” and offered the following 
practical guidance as to claim construction:
•  The extent of protection (the monopoly) 
is determined by the terms of the claims.
•  These are to be interpreted purposively—the 
inventor’s purpose being ascertained 
from the description and drawings.
•  Purpose is not however “the be-all and end-all”; 
at “the end of the day” one is “concerned 
with the meaning of the language used.”
 If, for example, a patentee has included an 
obvious “deliberate limitation” in a claim, 
this limitation has a meaning and cannot 
be disregarded. Equally, where a word or 
phrase with a particular contextual meaning 
is used, this word or phrase may not 
necessarily have that meaning in context.
• There is no general “doctrine of equivalents.”
Mayne Pharma v. Pharmacia Italia
INTERNATIONAL
India Adopts WTO Patent Law
Under legislation passed in late March, India 
will begin granting patent protection for 
pharmaceutical products, effectively prohibiting 
the domestic manufacture of low-cost generics. 
This is an important milestone for India, marking 
its compliance with its obligations under the 
WTO TRIPS (World Trade Organization Trade 
Related Intellectual Property Rights) regime. 
The new law provides that Indian companies 
producing generics prior to January 1, 2005, 
will be permitted to continue to do so, but 
only if they apply for a manufacturing license 
and pay a reasonable royalty to the patentee. 
Product patents granted under the new regime 
will remain in force for 20 years, during which 
time the patentee will have exclusive rights 
over the manufacture and sale of the drug.
Branded pharmaceutical companies 
should welcome the passage of this bill. 
Foreign filing strategies will have to be 
reviewed to capture the new protections 
afforded by this change in patent law.
ANTITRUST/COMPETITION
UNITED STATES
Appellate Court Upholds Legality of 
Hatch-Waxman Settlements between 
Branded and Generic Drug Companies
On March 8, 2005, the Eleventh Circuit Court 
of Appeals reversed a cease and desist order of 
the FTC and upheld the legality of agreements 
between a branded drug manufacturer and 
two generic drug manufacturers settling patent 
infringement litigation under the Hatch-Waxman 
Act (Schering-Plough Corp. v. FTC). The FTC had 
ruled that the settlements were a per se illegal 
market allocation because they involved payments 
by the branded company to the generics in 
exchange for the generics’ agreement not to 
market their products until certain dates. The 
Eleventh Circuit disagreed and reversed the 
order, holding that patents are presumed valid; 
that the branded company had an absolute 
right under its patent to exclude the generics 
until patent expiration; and, therefore, that the 
settlements—which provided for generic entry 
earlier than the expiration of the patent—were 
within the exclusionary scope of the patent. The 
court also held that any anticompetitive effects 
of the settlements were reasonably “ancillary” to 
the “clear” pro-competitive efficiencies resulting 
from the settlement of patent infringement suits.
“India will begin  
granting patent  
protection for  
pharmaceutical  
products.”
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The decision has potential far-reaching  
consequences, because a party aggrieved by  
a decision of the FTC may appeal to any court  
of appeals in which it does business. Thus, as a 
practical matter, if the decision in Schering stands 
(the FTC has filed a petition seeking an en banc 
review, and if unsuccessful, could seek review by 
the Supreme Court), it may become difficult, if 
not impossible, for the FTC to challenge most 
Hatch-Waxman settlements.
Schering-Plough v. FTC
EUROPE
Senior Executives Arrested on Suspicion  
of Price Fixing
Two senior executives of Goldshield Group plc 
were arrested on March 28, 2005, on suspicion 
of fixing the price of generic drugs. The arrests 
were made as part of an ongoing investigation 
by the UK Serious Fraud Office (SFO) into 
allegations that six drug companies fixed the 
prices of generic versions of common antibiotics 
(including the blood-thinning agent warfarin 
and the ulcer drug Zantac) in the late 1990s.
One of the companies under investigtion,  
Ranbaxy (UK) Ltd, reached a £4.5 million 
settlement with the Department of Health  
on April 1, 2005.
Following the introduction of the “cartel 
offense” by the Enterprise Act of 2002, 
it is an offense to dishonestly agree to fix 
prices, limit or prevent supply or production, 
share markets, or engage in bid-rigging.
The SFO’s investigation relates to alleged 
price fixing that took place before the 
introduction of the cartel offense. However, 
the arrests highlight the increasing willingness 
of the UK authorities to take action against 
individuals engaged in cartel activity. 
European Court of Justice Declines 
Jurisdiction in Syfait v. GlaxoSmithKline
Following the report published in the Spring 
2005 edition of PharmaBulletin, the ECJ stated, on 
May 31, 2005, that it does not have jurisdiction 
to rule on the issue referred by the Greek  
Competition Commission—namely, whether 
the protection of legitimate commercial interests 
can justify a restriction of supply by a dominant 
pharmaceutical company that is designed to 
limit parallel trade. The ECJ held that, because 
the Greek Competition Commission is not a 
“court or tribunal,” it is unable to refer questions 
for a preliminary ruling. The October 2004 
Opinion of the Advocate-General therefore 
provides the only guidance on this issue.
Syfait v. GlaxoSmithKline
STOP THE PRESS
Wilmer Cutler Pickering Hale and Dorr is 
pleased to welcome Jeffrey K. Francer to 
the firm. Jeffrey is an associate in the FDA 
Department and will advise clients regarding 
the regulation of drugs, biological products and 
medical devices. Prior to joining the firm, Jeffrey 
served as associate chief counsel of the FDA. 
We would like to give special thanks for this  
edition to Corinne Atton, Hollie Baker, Jeffrey  
Francer, Christopher Hutton, Peter Spaeth  
and Colleen Superko.
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